<DOC>
	<DOCNO>NCT01730053</DOCNO>
	<brief_summary>To evaluate reduction low-density lipoprotein cholesterol ( LDL-C ) alirocumab ( REGN727/SAR236553 ) add-on therapy LMT patient hypercholesterolemia high cardiovascular ( CV ) risk .</brief_summary>
	<brief_title>Study Alirocumab ( REGN727/SAR236553 ) added-on Rosuvastatin Versus Other Lipid Modifying Treatments ( LMT ) ( ODYSSEY OPTIONS II )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients LDLC great equal 70 mg/dL screen visit adequately control stable daily dose rosuvastatin , without LMT . OR 2 . Patients screen LDLC great equal 100 mg/dL adequately control stable daily dose rosuvastatin screen visit , without LMT . 1 . LDLC le 70 mg/dL screen visit patient history document cardiovascular disease ( CVD ) 2 . LDLC le 100 mg/dL screen visit patient without history document coronary heart disease ( CHD ) nonCHD CVD , risk factor 3 . Homozygous familial hypercholesterolemia ( FH ) ( clinically previous genotyping ) 4 . Recent ( within 3 month prior screen visit ) myocardial infarction ( MI ) , unstable angina lead hospitalization , percutaneous coronary intervention ( PCI ) , coronary bypass graft surgery ( CABG ) , uncontrolled cardiac arrhythmia , stroke , transient ischemic attack , carotid revascularization , endovascular procedure surgical intervention peripheral vascular disease 5 . Newly diagnose ( within 3 month prior randomization visit ) poorly control diabetes 6 . Presence clinically significant uncontrolled endocrine disease know influence serum lipid lipoprotein ( The inclusion/ exclusion criterion provide intend contain consideration relevant patient 's potential participation clinical trial ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>